Editorial Board About Us

J Curtis Nickel

All articles from this author are listed below.

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Claus G Roehrborn Michael K Brawer J Curtis Nickel F Pouliot B Shuch Arie S Belldegrun Naoki Yoshimura Alan W Partin Ellen Shapiro Dean G Assimos Michael B Chancellor Stacy Loeb

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 12, Number 3 Review Articles

Forensic Dissection of a Clinical Trial: Lessons Learned in Understanding and Managing Interstitial Cystitis

Management Update

J Curtis Nickel

A pharmaceutical company‚Äîsponsored post-registration clinical trial designed to determine the most effective dose of pentosan polysulfate for the treatment of interstitial cystitis (IC) reported negative results. However, because of a priori trial design features, important posthoc analyses were able to answer many of the important clinical issues on the epidemiology, diagnosis, and treatment of IC that to date had remained unanswered. Seven published follow-up reports based on data and outcomes from the original study evaluated the clinical significance of a positive Potassium Sensitivity Test, confirmed the O‚ÄôLeary-Sant Interstitial Cystitis Symptom Index as a valid and sensitive outcome measure, and determined that doses of pentosan polysulfate higher than the standard US Food and Drug Administration‚Äîapproved dose of 300 mg/d did not increase efficacy although increased duration of therapy increases the chance of symptom amelioration. Further analyses determined that sexual dysfunction is an important parameter to assess in IC and that successful therapy can improve sexual functioning. Finally, the data showed that symptom severity, quality of life (QoL), and sleep function are interrelated. Consequently, symptom improvement with therapy correlates with improvement in both sleep function and QoL. This post hoc forensic dissection of a clinical trial initially undertaken for simple regulatory reasons has significantly improved our understanding and management of the enigmatic condition we call IC. [Rev Urol. 2010;12(2/3):e78-e85 doi: 10.3909/riu0445]

Interstitial cystitis Pentosan polysulfate sodium Potassium sensitivity test

Volume 12, Number 1 Literature Reviews

Urologic Chronic Pelvic Pain Syndromes

Reviewing the Literature

J Curtis Nickel

Volume 13, Number 1 Meeting Reviews

Update on Urologic Pelvic Pain Syndromes

Meeting Review

Allan Gordon Daniel Shoskes Andrew P Baranowski Ragi Doggweiler Kenneth M Peters Michel Pontari Dean A Tripp J Curtis Nickel

"Highlights From the 2010 International Chronic Pelvic Pain Symposium and Workshop, August 29, 2010, Kingston, Ontario, Canada [Rev Urol. 2011;13(1):39-49 doi: 10.3909/riu0516]"

Urologic chronic pelvic pain syndromes Chronic prostatitis/chronic pelvic pain syndrome

Volume 14, Number 3 Book Reviews

a-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical Evidence

Treatment Update

Naji Touma J Curtis Nickel

The pathogenesis of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is multifactorial, making its treatment difficult. Multimodal therapy including a- adrenergic antagonists (a-blockers), anti-inflammatory agents, and other pain treatments may provide optimal management for CP/CPPS. Although a-blockers are the most prescribed drugs for patients with CP/CPPS, not all studies support their efficacy. A recent meta-analysis of small trials suggested that treatment with a-blockers, possibly in combination with antibacterial agents, is efficacious in relieving symptoms. Third-generation a1A blockers (silodosin, tamsulosin) may provide efficacy as well as reduced cardiovascular side effects. Future research should aim to identify potential biomarkers associated with treatment response. [Rev Urol. 2012;14(3/4):56-64 doi: 10.3909/riu0557] © 2013 MedReviews®, LLC

Adrenergic alpha-1 receptor antagonists Tamsulosin Silodosin Alfuzosin Prostatitis

Volume 18, Number 3 Meeting Reviews

Highlights From the 2016 American Urological Association Annual Meeting

Michael K Brawer Michael A Gorin Alan W Partin Michael B Chancellor Ellen Shapiro Dean G Assimos Benjamin M Brucker Stacy Loeb J Curtis Nickel

More than 2000 posters, abstracts, and videos were presented at the 2016 American Urological Association (AUA) Annual Meeting, held in San Diego, CA, from May 6 to 10, 2016. The editors of Reviews in Urology have culled an enormous volume of information from this premier source and present the findings that are most relevant to the practicing urologist. [Rev Urol. 2016;18(3):159-173 doi:10.3909/riu0717] © 2016 MedReviews®, LLC

Prostate cancer Active surveillance Disorders of sexual development Nephrolithiasis Overactive bladder Microbiome OnabotulinumtoxinA Hemorrhagic cystitis Inflammation Four kallikrein assay Genomic prostate score